| A replacement for warfarin: the search continues. | |
| | |
MedLine Citation:
|
PMID: 17576860 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
|
Authors:
|
John W Eikelboom; Jeffrey I Weitz |
Publication Detail:
|
Type: Comment; Editorial Date: 2007-06-18 |
Journal Detail:
|
Title: Circulation Volume: 116 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-07-10 Completed Date: 2007-08-17 Revised Date: 2009-02-10 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 131-3 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Anticoagulants / administration & dosage, therapeutic use* Clinical Trials, Phase II as Topic Factor Xa / antagonists & inhibitors Humans Morpholines / therapeutic use Thiophenes / therapeutic use Thrombosis / drug therapy* Vitamin K / antagonists & inhibitors Warfarin / adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Morpholines; 0/Thiophenes; 0/rivaroxaban; 12001-79-5/Vitamin K; 81-81-2/Warfarin; EC 3.4.21.6/Factor Xa |
| Comments/Corrections | |
Comment On:
|
Circulation. 2007 Jul 10;116(2):180-7
[PMID:
17576867
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study...
Next Document: Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA dec...